BN Business News
Add your company to Business Communicator →

Regulation & law · 29/11/2017

NIAID Considers Exclusive Patent License to GSK for HIV-Specific Antibody

The National Institute of Allergy and Infectious Diseases is considering granting an exclusive patent commercialization license to GlaxoSmithKline to develop and commercialize a novel, broad, and highly potent HIV-specific antibody.

Original source language: Federal Register — All DocumentsOpen original release →

Explore insights